Kornimate/medical-research-clean huggingface dataset:
effect of urtica dioica on glycemic control in patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: diabetes mellitus is the most common metabolic disorder worldwide. some herbs are traditionally used in treatment of type 2 diabetes mellitus (t2dm). urtica dioica (ud) or stinging nettle is traditionally used in morocco, turkey, brasil, jordan and with much frequency in northern iran. studies on animal models along with in vitro studies has shown hypoglycemic effect for aqueous extract of ud. this study aimed to investigate hypoglycemic effects of ud tea bags in patients with t2dm on glycemic control, insulin sensitivity, along with its effects on lipid profile (lp), blood pressure (bp), liver, and kidney function.

the study will be performed under randomized, double-blind, placebo controlled, and case-control design. the object of this study is patients with t2dm. patients are randomly assigned to start with placebo tea bags (3 tea bags as 2-gram tea bag steamed in boiling water for 20 minutes: mixture of bran powder which is already boiled in water twice plus spinach powder) in control groups and ud tea bags (3 tea bags as 2-gram tea bag steamed in boiling water for 20 minutes) in patients with t2dm for two months. every two weeks, fasting glucose, postprandial glucose after a standard breakfast, serum insulin, lipids, alanine amino transferase (alt), aspartate amino transferase (ast), creatinine (to calculate gfr), along with blood pressure will be measured. to the best of our knowledge, this is the first randomized clinical trial.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of t2dm * must be able to drink ud or placebo tea bags 3 times every day exclusion criteria: * insulin dependent diabetes * history of congestive heart failure within last 5 years (nyha class iii-iv) * history of significant pulmonary disease, myocardial infarction, cerebrovascular accident, or nephrotic syndrome within last 1 year * thyroid disease * known renal or hepatic insufficiency * gastric problem * history of ud or and other herb use in past 6 months * pregnancy or lactation * use of any herbal or supplement within past 6 months * use of an investigational drug (within 30 days prior to enrollment) * known maternal allergies * dumping syndrome

Keywords: type 2 diabetes mellitus urtica dioica (or stinging nettle) hypoglycemic agents
use of 4d-ice in conjunction with tee for left atrial appendage closure

Conditions: Atrial Fibrillation; Stroke

Summary: this is a prospective, single center, non-randomized study with two parallel arms intended to study if 4d intracardiac echocardiography (4d-ice) (nuvision, nuvera tm) will provide better visualization of the anatomical landmarks from the larger imaging volume and provide optimal intra procedural guidance similar to transesophageal echocardiography (tee) (ge 6vt-d ultrasound transducer) for left atrial appendage closure (laac). the study will enroll approximately 52 subjects and will be followed through 12 months.

standard intraprocedural guidance for transcatheter left atrial appendage closure (laac) employs a multi-modality integrated approach combining fluoroscopy for guiding the delivery system, and transesophageal echocardiography (tee) for intracardiac characterization to guide device selection and monitor procedural complications. successful implantation of the device is confirmed with contrast-enhanced fluoroscopy and color doppler flow imaging on tee. tee is the current gold standard for procedural guidance but requires general anesthesia (ga) to avoid patient motion and discomfort during the procedure. general anesthesia, however, is associated with pulmonary complications and patient discomfort due to endotracheal intubation. intraprocedural laac guidance under local anesthesia or conscious sedation might help mitigate these ga-related disadvantages and has motivated multiple clinical studies, establishing intracardiac echocardiography (ice) as a safe and feasible alternative to tee. the new generation of nuvision ice catheter offers a larger imaging volume of 90° x 90° with multiplanar reformatted (mpr) echo views for better visualization of anatomical landmarks and procedural guidance and aid in sizing of the device. this has a potential to improve outcomes and reduce procedure times while lowering healthcare costs. in this study, role of nuvision intracardiac echocardiographic (ice) catheter with tranesopheal echocardiography (tee) in predicting intra-procedural outcomes and success of implantation in patients undergoing left atrial appendage occlusion will be assessed.

Eligibility criteria:
inclusion criteria: * male/females * age:18-80 years * history of atrial fibrillation/atrial flutter * will have endocardial left atrial appendage closure (laac) with an amplatzer amulet or watchman flx device exclusion criteria: * inability or unwillingness of an individual to give written informed consent * patient not following with our practice after the procedure * complex anatomy for endocardial laac * thrombus in laa * patients with pericardial effusion in pre-op tee/ccta * patients currently pregnant (serum beta hcg completed when labs obtained for the procedure are completed)
impact of an operating room nurse pre-operative dialogue in patients undergoing major visceral surgery

Conditions: Anxiety; Post Operative Pain; Postoperative Nausea; Postoperative Complications; Satisfaction, Patient

Summary: single-center, open label, randomized controlled trial of a preoperative nursing dialogue in patient undergoing major visceral surgery aiming in evaluating its impact on patients' anxiety, satisfaction and early postoperative outcomes.


Eligibility criteria:
inclusion criteria: * patient undergoing elective major visceral surgery * hospitalization the day before surgery * sufficient command of french language exclusion criteria: * emergency procedures (after unplanned admission) * inability to obtain informed consent or refusal * inability to follow intervention
real-time ecounselling for nicotine addiction

Conditions: Nicotine Use Disorder

Summary: the goal of this clinical trial is to pilot an ehealth intervention (real-time telecounselling) in nicotine addiction. the main questions it aims to answer are: is the intervention likely to be efficacious in preventing an increase in abstinence? is the intervention likely to be efficacious in preventing an increase in nicotine consumption? is the intervention likely to be efficacious in influencing readiness to quit nicotine? how feasible is the intervention for developing a larger-scale trial? researchers will compare a range of outcome measures between the active and control arms, to see if a pilot ehealth intervention can successfully treat nicotine addiction.

the goal of this clinical trial is to pilot an ehealth intervention in nicotine addiction (real-time telecounselling) . it will also attempt to better understand the psychology of nicotine addiction and craving regarding consumption behaviour. the main questions it aims to answer are: is the intervention likely to be efficacious in preventing an increase in abstinence? is the intervention likely to be efficacious in preventing an increase in nicotine consumption? is the intervention likely to be efficacious in influencing readiness to quit nicotine? how feasible is the intervention for developing a larger-scale trial? researchers will compare outcomes pre and post intervention in the active arm, and also between active and control arms, to ascertain the treatment effect of the intervention on primary (nicotine consumption, abstinence) and secondary (self-efficacy, readiness to quit, decisional balance) measures, in tests of efficacy. following randomisation, participants will be allocated to either the active arm or the control arm. in the active arm, participants will undergo six weekly sessions of real-time cbt-mi (cognitive behavioural therapy with motivational interviewing), with each session lasting approximately 45 to 60 minutes. in the control arm: a wait list control group (wlcg) will denote the comparator, who will undergo screening and assessment only.

Eligibility criteria:
inclusion criteria: 1. age: 18-65 years old 2. self reported smoking ≥ 5 cigarettes per day, or regular vaper of \> 0mg nicotine 3. desire to quit nicotine consumption 4. willing to set a quit date 5. able to provide written informed consent to participate - exclusion criteria: 1. enrolled in another behavioural intervention programme 2. pregnant, breastfeeding or planning to become pregnant. 3. individuals currently experiencing a problematic relationship with alcohol or drugs 4. documented cognitive impairment 5. individuals with a phq-9 score of ≥ 14 or a gad-7 score of \>12.

Keywords: smoking cessation vaping public health ehealth nicotine addiction feasibility
comparative study of intestinal color ultrasound and capsule endoscopy in monitoring crohn's disease

Conditions: Digestive System Disease; Inflammatory Bowel Diseases; Crohn Disease; Crohn Disease of Small Intestine

Summary: the disease activity index under intestinal color ultrasound was evaluated by sus-cd, and the disease activity index under capsule endoscopy was evaluated by cecdai. all subjects underwent intestinal color ultrasound and capsule endoscopy at baseline and at the third month of treatment. to compare the correlation between sus-cd and cecdai before and after treatment, and to compare the role of intestinal color ultrasound and capsule endoscopy in monitoring crohn's disease in small intestine.

the disease activity index under intestinal color ultrasound was evaluated by sus-cd, and the disease activity index under capsule endoscopy was evaluated by cecdai. active lesions under intestinal color ultrasound were defined as sus-cd ≥ 1, and active lesions under capsule endoscopy were defined as cecdai ≥ 3.9. all subjects underwent intestinal color ultrasound and capsule endoscopy at baseline and 3 months after treatment. to compare the correlation between sus-cd and cecdai before and after treatment, and to compare the role of intestinal color ultrasound and capsule endoscopy in monitoring crohn's disease in small intestine.

Eligibility criteria:
inclusion criteria: * 1.patients diagnosed with crohn's disease according to the 2019 european guidelines for crohn's disease; * 2.at the time of inclusion, there were active lesions under color ultrasound or capsule endoscopy; * 3.voluntarily sign an informed consent form. exclusion criteria: * 1.patients with contraindications for capsule endoscopy; * 2.in the judgment of the investigator, it is not suitable to participate in this study.

Keywords: intestinal color ultrasound capsule endoscopy sus-cd cecdai
bendamustine hydrochloride in treating patients with previously treated multiple myeloma

Conditions: Multiple Myeloma; Plasma Cell Leukemia

Summary: this phase i trial studies the side effects and best dose of bendamustine hydrochloride in treating patients with previously treated multiple myeloma. drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

primary objectives: i. to identify a maximum tolerated dose of bendamustine (bendamustine hydrochloride) in patients with multiple myeloma. secondary objectives: i. to evaluate the safety of escalating doses of bendamustine in patients with multiple myeloma. ii. to describe the response after bendamustine outline: this is a dose-escalation study. patients receive bendamustine hydrochloride intravenously (iv) over 60-180 minutes on days 1 and 2.

Eligibility criteria:
inclusion criteria: 1. patients with multiple myeloma who have not achieved a cr following at least 4 cycles of induction therapy 2. age up to 80 years 3. ecog performance status of 0 or 1 4. left ventricular ejection fraction =/\> 40%. no uncontrolled arrhythmias or symptomatic cardiac disease 5. fev1, fvc and dlco =/\> 40%. no symptomatic pulmonary disease. 6. serum bilirubin \ 1 l prior to drainage. 7. hiv negative 8. negative beta hcg test in woman with child bearing potential, defined as not post-menopausal for 12 months or no previous sterilization 9. patients or guardian able to sign informed consent 10. availability of previously collected autologous stem cells (at least 3.0 x 106 cd34 cells/kg) 11. calculated gfr \> 50 ml/minute exclusion criteria: 1. patients with uncontrolled hypertension (systolic \> 140, diastolic \> 90 despite antihypertensive therapy 2. patients with uncontrolled bacteria, viral or fungal infections (currently taking medication and progression of clinical symptoms) 3. new york heart association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities 4. relapsed/refractory myeloma

Keywords: partial response
clinical study to determine if ecopipam can reduce urges to gamble

Conditions: Pathological Gambling

Summary: this study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with pathological gambling.

the purpose of this study is to determine if ecopipam is able to stop urges to gamble in patients diagnosed with pathological gambling. nerves communicate with each other by releasing chemicals called "neurotransmitters". one of these neurotransmitters in the brain is called "dopamine". after dopamine is released by the nerve it "talks" to other nerves by interacting with receptors that are unique to that neurotransmitter. ecopipam is a drug that selectively blocks one family of dopamine receptors. some scientists believe that the urge to gamble is related to having too much dopamine in the brain. by blocking the receptors that dopamine uses, ecopipam may be able to relieve the urge to gamble.

Eligibility criteria:
inclusion criteria: * subject must be diagnosed with pathological gambling according to dsmiv criteria * subject must have at least 2 episodes of gambling behavior within the previous 2 weeks before screening * subject must have gambling urges of at least moderate intensity exclusion criteria: * subjects must not have unstable medical illness or clinically significant abnormalities on lab tests, ecg, or physical exam * subjects with major depressive episode within the last 2 years * subjects with a history of attempted suicide * subjects with first degree relative with major depressive episode that resulted in hospitalization, attempted or completed suicide * subjects with a history of epilepsy or seizures * subjects with a myocardial infarction (heart attack) with in the last 6 months * subjects with a lifetime history of bipolar disorder, dementia, schizophrenia, or any psychotic disorder * subjects with current of recent dsm-iv diagnosis of substance abuse or dependence (with the exception of nicotine)

Keywords: pathological gambling ecopipam dopamine
probiotics for reduction of markers in subjects with allergy

Conditions: Hay Fever; Birch Pollen Allergy

Summary: in vitro studies reveal immunomodulatory effects of probiotic bacteria that are strain-dependent. differential immunomodulatory in vitro capacities can not be extrapolated directly to in vivo efficacy. thus, in vitro screening should be followed by comparative analysis of the selected immunomodulatory probiotic strains in an in vivo setting. birch pollen allergy is one of the most common forms of respiratory allergy in european countries, and recognized by a th2-skewed immune system. five lactobacillus strains will be evaluated for their immunomodulatory properties in birch pollen sensitive subjects outside the hay fever season. a double-blind placebo-controlled parallel study will be performed in which subjects with a proven birch pollen allergy will consume one of 5 different probiotic yoghurts containing 4 l. plantarum strains and 1 l. casei strain or a placebo yoghurt. blood samples are collected at the start and after 4 weeks. immune parameters are determined in serum and peripheral blood mononuclear cell cultures (hpbmc) derived from these subjects.


Eligibility criteria:
inclusion criteria: * birch pollen sensitive subjects * positive rast or intracutane skintest * age 18-50 * signed informed consent form exclusion criteria: * use of probiotics * known allergy for pets (home setting) * use of medication influencing the immune system * use of antibiotics * lactose intolerance * pregnancy * infection
sun light exposure and vitamin d level in nursing home

Conditions: Nursing Home; Vitamin D Deficiency

Summary: objective: the aim of the present study was to determine the effect of nursing interventions and sunlight exposure to reach optimum vitamin d levels by individuals living in nursing homes on vitamin d levels. material method: in the first stage of this two-stage randomized-controlled experimental study with pretest-posttest design conducted in june - august 2018 period in the nursing home in central town of tokat province, the questionnaire prepared by the researcher, standardized mini mental test, fitzpatrick skin typing questionnaire and katz index of activities of daily living were applied. intervention (n=20) and control (n=20) groups were established with individuals using simple random method according to age, gender, skin type and vitamin d level. in the second stage, 30-35% of the body surface area of individuals in the intervention group was exposed to sunlight five days a week in july. for the participants in the control group, sunbathing was not offered. 25(oh)d, calcium, parathormone, phosphorus, alkaline phosphatase and albumin levels of all individuals were measured in blood samples taken at the beginning and end of the study. two-way mixed anova, mann-whitney u test, wilcoxon signed rank test and chi-square tests were used to evaluate the data.


Eligibility criteria:
inclusion criteria: * individuals (25 women and 41 men) who lived in nursing home during june 27, 2018 and august 01, 2018 period * 60 years and older * able to perform their daily life activities independently * agreed to participate in the study exclusion criteria: * malignancies * advanced liver and kidney failure * history of gastric-bowel operation * skin disease that could prevent sun exposure * hyperparathyroidism * malabsorption * use of drugs that affect the levels of vitamin d, calcium, pth and phosphorus and albumin
relationship between ct- value with prognosis in covid-19 patients

Conditions: COVID-19

Summary: evaluate the relationship between cycle threshold number with final prognosis in covid-19 patients

evaluate the relationship between cycle threshold number with final prognosis in covid-19 patients

Eligibility criteria:
inclusion criteria: * covid-19 pcr positive exclusion criteria: -

Keywords: covid-19
sleep enhancement training study for experienced shiftworkers

Conditions: Shift-Work Sleep Disorder

Summary: the purpose of this study is to determine if a modified version of the sleep enhancement fatigue reduction training (sefrt) system can improve sleep and health-related symptoms and quality of life in experienced shift-working nurses.


Eligibility criteria:
inclusion criteria: * english-speaking nurses * scheduled to work at least 2 consecutive night shifts per week during the next 3 months * ≥40 years of age * experiencing disturbed sleep related to night-shift exclusion criteria: * current diagnosis of sleep disorder or affective illness

Keywords: shift-work sleep nurse relaxation
efficacy and safety of mildronate for acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: this study seeks to evaluate the efficacy and safety of mildronate injection in treating acute ischemic stroke

a randomized, double-blind, placebo-controlled phase ii multicenter trial is conducted to evaluate the efficacy and safety of mildronate injection in patients with acute ischemic stroke. patients will be randomized to receive a 14-day treatment of placebo or mildronate (500mg/5ml/each).primary end-point is the modified rankin scale at 3 monthes. secondary end-point is the nihss scores and the barthel index at 8 days and 15days. the safety end-point is defined as the incidence of adverse events, the change of samples for routine laboratory tests and vital signs. analysis is by intention to treat.

Eligibility criteria:
inclusion criteria: - have a clinical diagnosis of acute ischemic stroke have ct or mri brain imaging nihss scores:5\~22 on the first stage exclusion criteria: - have other intracranial pathologies are pregnant or nursing have significant drug or alcohol misuse have been in a clinical trial in the past 3 months are unlikely to be available for follow-up have been given thrombolytic therapy or medication forbidden by study protocol have a neurological or psychiatric disease

Keywords: randomized trial acute ischemic stroke mildronate
99mtc-rhannexin v-128 imaging for carotid atherosclerosis

Conditions: Carotid Artery Plaque

Summary: this was a single-center, single-dose, study comprising a proof of concept (poc) part and a subsequent phase ii part. the study was being done to assess the ability of the radiotracer 99mtc-rhannexin v-128 to image atherosclerotic plaque that might rupture and break off artery walls. this is caused by apoptosis or cell death in the plaque. these ruptured plaques can block blood circulation in the arteries causing a lack of oxygen to the tissues. atherosclerotic plaques can build up on any artery in the body.

the sponsor decided to terminate the study earlier than planned due to strategic decisions to focus the aaa development portfolio on oncology theragnostics and not based on safety concerns. novartis acquired advanced accelerator applications sa.

Eligibility criteria:
inclusion criteria: for all participants: 1. males and females age 18 years or greater 2. able and willing to comply with the study procedures 3. negative pregnancy test for women of childbearing potential at screening and on the day of administration of 99mtc-rhannexin v-128. for participants with carotid artery disease: 4. evidence of 50% or more carotid stenosis in one or more carotid arteries on carotid ultrasound within 2 years; 5. evidence of 50% or more carotid stenosis in the most recent us imaging within 8 weeks prior to 99mtc-rhannexin v-128 administration for control participants: 6. no significant carotid artery disease on carotid ultrasound; 7. no clinically significant abnormalities in baseline laboratory values. exclusion criteria: 1. previous carotid stending, endarterectomy or stroke; 2. diagnosis of vasculitis, dissection, or non-atherosclerotic carotid disease (ehlers-danlos, marfans); 3. pregnancy or lactation; 4. history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment; 5. know hypersensitivity to the investigational product or any of its components; 6. claustrophobia or inability to lie still in a supine position; 7. participation in another clinical trial within 4 weeks before study inclusion, except for patients who have participated or who are currently participating in a study without any study drug administration; 8. unwillingness to provide consent.

Keywords: carotid stenosis carotid artery narrowing carotid artery plaque carotid artery stenosis carotid artery ulcerating plaque carotid ulcer common carotid artery stenosis external carotid artery stenosis internal carotid artery stenosis plaque, ulcerating, carotid artery stenosis, common carotid artery stenosis, external carotid artery ulcerating plaque, carotid artery